Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
10.65
-0.29 (-2.65%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Phathom Pharmaceuticals Employees
Phathom Pharmaceuticals had 371 employees as of December 31, 2025. The number of employees decreased by 56 or -13.11% compared to the previous year.
Employees
371
Change (1Y)
-56
Growth (1Y)
-13.11%
Revenue / Employee
$552,270
Profits / Employee
-$423,989
Market Cap
845.93M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 371 | -56 | -13.11% |
| Dec 31, 2024 | 427 | -25 | -5.53% |
| Dec 31, 2023 | 452 | 340 | 303.57% |
| Dec 31, 2022 | 112 | 35 | 45.45% |
| Dec 31, 2021 | 77 | 22 | 40.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 465 |
| Pharming Group | 407 |
| Geron | 258 |
| DBV Technologies | 161 |
| Sana Biotechnology | 142 |
| Solid Biosciences | 121 |
| Odyssey Therapeutics | 100 |
| Theravance Biopharma | 90 |
PHAT News
- 20 hours ago - Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026 - GlobeNewsWire
- 27 days ago - Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial - TheFly
- 27 days ago - Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 5 weeks ago - Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Needham pharmaceuticals analysts hold analyst/industry conference call - TheFly
- 2 months ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - GlobeNewsWire